Institute for Skin Advancement

Calgary, Alberta T3E 0B2

0 studies enrolling now · 13 studies all time

What they study most

Acne Vulgaris, Atopic Dermatitis, Dermatitis, Atopic, Eczema, Non-segmental Vitiligo, Plaque Psoriasis, Psoriasis

Studies at this site

• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) — Completed
• Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 — Completed
• Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy — Completed
• A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis — Completed
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis — Completed
• A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris — Completed
• A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris — Completed
• A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis — Completed
• A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis — Completed